Emerging manufacturing processes to generate regenerative advanced therapies can involve extensive genomic and/or epigenomic manipulation of autologous or allogeneic cells. These cell engineering processes need to be carefully controlled and standardized to maximize safety and efficacy in clinical trials. Engineered biomaterials with smart and tunable properties offer an intriguing tool to provide or deliver cues to retain stemness, direct differentiation, promote reprogramming, manipulate the genome, or select functional phenotypes. This review discusses the use of engineered biomaterials to control human cell manufacturing. Future work exploiting engineered biomaterials has the potential to generate manufacturing processes that produce standardized cells with well-defined critical quality attributes appropriate for clinical testing.

产生再生先进疗法的新兴制造工艺可能涉及自体或同种异体细胞的广泛基因组和/或表观基因组操作。这些细胞工程过程需要仔细控制和标准化，以最大限度地提高临床试验的安全性和有效性。具有智能和可调特性的工程生物材料提供了一种有趣的工具，可以提供或传递线索以保留干性、直接分化、促进重编程、操纵基因组或选择功能表型。这篇综述讨论了使用工程生物材料来控制人类细胞制造。未来利用工程生物材料的工作有可能产生制造工艺，生产具有明确定义的适合临床测试的关键质量属性的标准化细胞。